The latest price target for Phathom Pharmaceuticals (NASDAQ:PHAT) was reported by Barclays on December 9, 2025. The analyst firm set a price target for $16.00 expecting PHAT to rise to within 12 months (a possible 11.89% upside). 18 analyst firms have reported ratings in the last year.

The latest analyst rating for Phathom Pharmaceuticals (NASDAQ:PHAT) was provided by Barclays, and Phathom Pharmaceuticals initiated their equal-weight rating.

The last upgrade for Phathom Pharmaceuticals Inc happened on May 11, 2023 when Evercore ISI Group raised their price target to N/A. Evercore ISI Group previously had an in-line for Phathom Pharmaceuticals Inc.

There is no last downgrade for Phathom Pharmaceuticals.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Phathom Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Phathom Pharmaceuticals was filed on December 9, 2025 so you should expect the next rating to be made available sometime around December 9, 2026.

While ratings are subjective and will change, the latest Phathom Pharmaceuticals (PHAT) rating was a initiated with a price target of $0.00 to $16.00. The current price Phathom Pharmaceuticals (PHAT) is trading at is $14.30, which is within the analyst’s predicted range.